[2006 technology monitoring report: clinical practice guideline: use of FDG-PET in kidney, prostate, testis and bladder cancers].
Bourguet
Patrick
P
Comité rédacteur SOR, INCA, FNCLCC, La Ligue, FHF FNCHRU, FFC et AFU, Centre Eugène Marquis, Rennes, France. patrick.bourget@rennes.fnclcc
Planchamp
François
F
Montravers
Françoise
F
Vincendeau
Sébastien
S
D019788:Fluorodeoxyglucose F18; D005602:France; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging*; D008297:Male; D013677:Medical Laboratory Science; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging*; D019275:Radiopharmaceuticals; D013736:Testicular Neoplasms / Q000000981:diagnostic imaging*; D001749:Urinary Bladder Neoplasms / Q000000981:diagnostic imaging*
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18